JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.